Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target
Faiza Javaid, Camilla Pilotti, Carlotta Camilli, David Kallenberg, Calise Bahou, Jack Blackburn, James R. Baker, John A. Greenwood, Stephen E. Moss, Vijay Chudasama
Abstract
LRG1 is present abundantly in the microenvironment of many tumours. LRG1 targeting through the reported non-internalising ADC presents a novel and effective proof-of-concept <italic>en route</italic> to improving the efficacy of cancer therapeutics.
Topics & Concepts
Monoclonal antibodyIn vivoCancer researchChemistryConjugateDipeptideIn vitroAntibodyAntibody-drug conjugateGlycoproteinLinkerPeptideCell biologyMedicineBiochemistryBiologyComputer scienceImmunologyOperating systemBiotechnologyMathematicsMathematical analysisClusterin in disease pathologyFerroptosis and cancer prognosisS100 Proteins and Annexins